ASX:BDA - BOD Australia Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
A$0.30 +0.01 (+3.51 %)
(As of 05/20/2019 04:00 PM ET)
Previous CloseA$0.29
Today's RangeA$0.27 - A$0.30
52-Week RangeA$0.26 - A$0.72
Volume53,416 shs
Average VolumeN/A
Market Capitalization$20.47 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BOD Australia Limited operates as a developer, manufacturer, distributor, and marketer of plant-based medicinal cannabis, health and supplement products, and cosmetic solutions primarily in Australia. Its medicines portfolio includes Enterofytol for treating irritable bowel syndrome; and SediStress, which is used for the reduction of stress and anxiety. The company distributes its products through a channel network of approximately 900 pharmacies. It offers products under the SediStress, BIOEFFECT, PINPOINT, Flexofytol, Enterofytol, MamaCare, and Pommade Devine brands. Bod Australia Limited has a research collaboration agreement with Cannabis Access Clinics. The company is based in Double Bay, Australia.

Receive BDA News and Ratings via Email

Sign-up to receive the latest news and ratings for BDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Household & Personal Products
Sub-IndustryN/A
SectorConsumer Defensive
CUSIPN/A
CIKN/A
Phone61 2 9199 5018

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.52 million
Cash FlowA$0.11 per share
Book ValueA$0.09 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$20.47 million
Next Earnings DateN/A
OptionableNot Optionable

BOD Australia (ASX:BDA) Frequently Asked Questions

What is BOD Australia's stock symbol?

BOD Australia trades on the ASX under the ticker symbol "BDA."

Has BOD Australia been receiving favorable news coverage?

Press coverage about BDA stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BOD Australia earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of BOD Australia's key competitors?

Who are BOD Australia's key executives?

BOD Australia's management team includes the folowing people:
  • Ms. Joanne Patterson, CEO, Director & Member of Medical Advisory Board
  • Mr. Craig Weller, COO & Member of Medical Advisory Board
  • Mr. George Livery, Exec. Chairman (Age 52)
  • Dr. Adele Hosseini, Chief Scientific Officer & Member of Medical Advisory Board
  • Mr. Stephen Thompson, Exec. Director

What is BOD Australia's stock price today?

One share of BDA stock can currently be purchased for approximately A$0.30.

How big of a company is BOD Australia?

BOD Australia has a market capitalization of $20.47 million and generates $1.52 million in revenue each year.

What is BOD Australia's official website?

The official website for BOD Australia is http://bodaustralia.com.

How can I contact BOD Australia?

The company can be reached via phone at 61 2 9199 5018.


MarketBeat Community Rating for BOD Australia (ASX BDA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  3 (Vote Outperform)
Underperform Votes:  3 (Vote Underperform)
Total Votes:  6
MarketBeat's community ratings are surveys of what our community members think about BOD Australia and other stocks. Vote "Outperform" if you believe BDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Featured Article: What are CEFs?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel